Numbers of all fractures occurring in men, arranged in order of decreasing mean age, and with proportion of each of the fracture types in patients over 50, 65, and 75 years of age. by Camilla Bergh (9904522)

“…<p>Numbers of all fractures occurring in men, arranged in order of decreasing mean age, and with proportion of each of the fracture types in patients over 50, 65, and 75 years of age.…”

Tax expression is associated with decreased cellular motility. by Saumya Ramanayake (7879091)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

%-change after 3 and 12 months of hormone therapy in trans women and trans men. by Moya H. Schutte (12245290)

Subjects:

Inflammation and hemostasis markers at 0, 3 and 12 months in trans men (absolute values). by Moya H. Schutte (12245290)

Subjects:

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Definitions of the features selected [50]. by Yu Zhang (12946)

Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s. by Djaloul Karboua (16510091)

“…<p>Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s.…”

genotyping by 50K ovine SNP chip by Pouya Zamani (20131050)

Foldases and holdases each decrease the level of unfolded protein. by Adam MR de Graff (9767829)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

Characteristics of patients with AKI diagnosed using eKDIGO only by the decrease in sCr (deKDIGO) and no AKI. by Marina Wainstein (12437091)

Frequency of occurrence (%) of decreased performances in relation to gender. by Philip X. Fuchs (11027636)

Growth on stiff substrate results in mild lifespan extension but a decrease in organismal health. by Maria Oorloff (19658113)

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

Inflammation and hemostasis markers at 0, 3 and 12 months in trans women (absolute values). by Moya H. Schutte (12245290)

Subjects:

Hormone concentrations, body mass index and blood pressure at baseline and after 3 and 12 months of hormone therapy. by Moya H. Schutte (12245290)

Subjects:

OLS regressions: Top 50 authors per field. by Sergey V. Popov (6719075)

Exercise test characteristics for identifying stenosis ≥ 50% in any limb among the 60 limbs with normal ABIs (> 0.91). by O. Stivalet (6890189)